About Stealth BioTherapeutics Corp (MITO) — Dividend Analysis 2026
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
Is MITO a good dividend investment in 2026?
MITO offers a 625.00% forward yield with a 50% payout ratio. Strand Safety Score: 30/100 (High Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
MITO DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your MITO portfolio grows to $4012176.83M vs $635.0K without reinvestment. This is the compound interest effect in action.
MITO dividend growth history & forecast
MITO has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 625.00%.
Company generates negative FCF ($-45M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.1B → -0.1B → -0.1B
30 / 30 pts
30/30
Net income grew for 2 consecutive years — strong earnings momentum
OVERALL ASSESSMENT
Dividend sustainability questionable — consider alternative income stocks.
STRAND SCORE
30
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 MITO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MITO.
Gross yield
625.00%
Tax rate
15.00%
After-tax yield
531.25%
Real yield (−CPI)
528.45%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
625.00%
622.20%
$62,500 / yr
🇺🇸 US Taxable (15%) ✓
15%
531.25%
528.45%
$53,125 / yr
🇺🇸 US Taxable (20%)
20%
500.00%
497.20%
$50,000 / yr
🇬🇧 UK ISA
0%
625.00%
622.20%
$62,500 / yr
🇬🇧 UK Taxable
8.75%
570.31%
567.51%
$57,031 / yr
🇨🇦 TFSA
0%
625.00%
622.20%
$62,500 / yr
🇨🇦 CA Taxable
25%
468.75%
465.95%
$46,875 / yr
🇦🇺 Super (pension)
15%
531.25%
528.45%
$53,125 / yr
🇦🇺 AU Taxable
30%
437.50%
434.70%
$43,750 / yr
🇩🇪 DE Taxable
26.375%
460.16%
457.36%
$46,016 / yr
🇫🇷 FR Taxable
30%
437.50%
434.70%
$43,750 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MITO Income Goal & Break-Even
Dividend Break-Even
1yr
Years for dividends to fully repay your MITO investment of $0.32/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$1004647.96M
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$1004647.96M
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in MITO for:
Shares needed
14,118
Capital required
$4,518
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MITO Dividend Payment Schedule
MITO pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 MITO vs Healthcare Benchmarks
How MITO compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+622.20% vs sectorBetter
MITO
625.00%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
MITO
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
MITO
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MITO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MITO Insider Activity
No recent SEC filings reported in the last 90 days.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MITO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →